Latest research in the hemoglobinopathy space has brought an experimental gene therapy, giving those who suffer the potential to make functional hemoglobin molecules.
A new, FDA-approved therapeutic monoclonal antibody with a novel target is the first and only MS treatment for the primary-progressive population.
Earning its place amid other new innovative medical technology are Bluetooth-enabled pacemaker devices to remedy this issue of disconnection between patients and their cardiac treatment.
A new combination drug, FDA approved in October 2019, is providing CF relief for patients with the most common CF gene mutation (F508 del) – estimated to represent 90% of individuals living with CF.
A new, approved fixed-dose combination medication has vastly improved hepatitis C treatment. More than 90% effective for hepatitis C genotypes 1-6, the treatment represents an effective option.
Unlike mechanical ventilation, b-CPAP is a non-invasive ventilation strategy – delivering continuous positive airway pressure to newborns to maintain lung volumes during exhalation.
COVID-19 saw increased adoption of telemedical practices. An increasingly virtual care model & increased consumer adoption came by way of fundamental shifts in policy at government & provider levels.
The vacuum-induced device represents another minimally-invasive tool for clinicians to battle the complication & provides a low tech solution that is potentially translatable to developing countries.
Known for their success in women’s cancers, two PARP inhibitors have been demonstrated to delay the progression of prostate cancer in men. Both were approved in May 2020 for prostate cancer.
Actively prescribed in 2020 with no signs of slowing adoption in 2021, this new FDA-approved class of medication for migraine sufferers is helping countless individuals reclaim their lives.